At TCT Connect, investigators presented the 30-day primary endpoint analysis of the Disrupt CAD III study, the largest and most rigorous coronary IVL study to date.
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
